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Introduction
With the increasing potential for targeted therapies in
autoinflammatory diseases, there is the need for validated
and standardized assessment tools which can be used to
evaluate the level of disease activity and response to ther-
apy. An international collaboration, initiated by Assistance
Publique-Hôpitaux de Paris (APHP) in association with
the Paediatric Rheumatology International Trials Organi-
zation (PRINTO at http://www.printo.it) and supported by
the EUROFEVER and EUROTRAPS networks, has pre-
viously designed the content and the preliminary scoring
of an Auto-Inflammatory Disease Activity Index (AIDAI)
Objectives
To validate the AIDAI score in the four major heredi-
tary recurrent fever syndromes (HRFs): familial Mediter-
ranean fever (FMF), mevalonate kinase deficiency
(MKD), tumor necrosis factor receptor-associated peri-
odic syndrome (TRAPS), and cryopyrin-associated peri-
odic syndromes (CAPS).
Methods
In 2010, an international collaboration established the
content of a disease activity tool for HRFs. Patients
completed a one-month prospective diary with 12 yes/
no (dichotomous) items prior to a clinical appointment
during which their physician assessed their disease activ-
ity by a questionnaire. Eight international experts in
auto-inflammatory diseases evaluated patient’s disease
activity by a blinded web-evaluation and a nominal
group technique consensus conference with their con-
sensus judgment considered as gold standard. Sensitiv-
ity/specificity/accuracy measures and the ability of the
score to discriminate active versus inactive patients via
the best cut-off score were calculated by a receiver oper-
ating characteristic (ROC) analysis.
Results
Consensus was achieved for 98/106 (92%) cases (39
FMF, 35 CAPS, 14 TRAPS and 10 MKD) with 26
patients declared as having inactive disease and 72 active
disease. The median total AIDAI score was14 (range =
0-175). An AIDAI cut-off score ≥ 9 discriminated active
versus inactive patients, with sensitivity/specificity/accu-
racy of 89%/92%/90% respectively and an area under the
curve of 98% (95%CI = 96% > 100%).
Conclusion
The AIDAI score is a valid and simple tool for the
assessment of disease activity in FMF/MKD/ TRAPS/
CAPS This tool is easy to use in clinical practice and
has the potential to be used as a standard efficacy mea-
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